Our top pick for
Tyme Technologies, Inc is a biotechnology business based in the US. Tyme Technologies shares (TYME) are listed on the NASDAQ and all prices are listed in US Dollars. Tyme Technologies employs 18 staff and has a market cap (total outstanding shares value) of USD$139.9 million.
|Latest market close||USD$1.1|
|52-week range||USD$0.85 - USD$2.04|
|50-day moving average||USD$0.9557|
|200-day moving average||USD$1.1734|
|Wall St. target price||USD$8.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.28|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-05)||-20.29%|
|1 month (2020-12-12)||N/A|
|3 months (2020-10-12)||8.91%|
|6 months (2020-07-12)||N/A|
|1 year (2020-01-12)||N/A|
|2 years (2019-01-12)||N/A|
|3 years (2018-01-12)||6.69|
|5 years (2016-01-12)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-89.55%|
|Return on equity TTM||-260.08%|
|Market capitalisation||USD$139.9 million|
TTM: trailing 12 months
There are currently 3.5 million Tyme Technologies shares held short by investors – that's known as Tyme Technologies's "short interest". This figure is 0.8% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting Tyme Technologies shares can be evaluated.
Tyme Technologies's "short interest ratio" (SIR) is the quantity of Tyme Technologies shares currently shorted divided by the average quantity of Tyme Technologies shares traded daily (recently around 256343.75928678). Tyme Technologies's SIR currently stands at 13.46. In other words for every 100,000 Tyme Technologies shares traded daily on the market, roughly 13460 shares are currently held short.
However Tyme Technologies's short interest can also be evaluated against the total number of Tyme Technologies shares, or, against the total number of tradable Tyme Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tyme Technologies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Tyme Technologies shares in existence, roughly 30 shares are currently held short) or 0.0437% of the tradable shares (for every 100,000 tradable Tyme Technologies shares, roughly 44 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Tyme Technologies.
Find out more about how you can short Tyme Technologies stock.
We're not expecting Tyme Technologies to pay a dividend over the next 12 months.
Tyme Technologies's shares were split on a 4:1 basis on 26 September 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Tyme Technologies shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Tyme Technologies shares which in turn could have impacted Tyme Technologies's share price.
Over the last 12 months, Tyme Technologies's shares have ranged in value from as little as $0.85 up to $2.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tyme Technologies's is 0.7661. This would suggest that Tyme Technologies's shares are less volatile than average (for this exchange).
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.